??the FDA failing to grant permission to proceed and placing the clinical trial on hold; ??the FDA's willingness to review our TZP-102 application under the fast track development program; ??subjects failing to enroll or remain in our trials at the rate we expect; ??a facility manufacturing our product candidates being ordered by the FDA or other government or regulatory authorities to